The Institute for Clinical and Economic Review isn’t taking a new group of migraine drugmakers to task over high costs. But it does have some suggestions for payers about how to manage the drugs. More: ICER to payers: Go easy
read moreAs officials prepare for President Donald Trump’s visit to the U.K. next week—and amid plans for major protests while he’s there—some Big Pharma CEOs have been invited to a black-tie dinner with Trump and Prime Minister Theresa May, the Financial
read moreIt’s no secret that Takeda is taking on a huge debt load to make the $62 billion Shire acquisition happen. Now, it’s looking to fill some of the financial gap by selling its old headquarters in Osaka, Japan. More: Takeda’s
read moreTwo years ago, Finland-based Fermion Oy decided it needed to replace the oldest manufacturing unit at its plant in Hanko. Now, that unit is ready to go. More: Finland's Fermion has completed an API plant expansion Source: fierce
read moreCelgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone. More: Data show Imnovid-based triple therapy PFS benefit in blood cancer
read moreThe vast majority of the public would be willing to accept tax increases to secure significant improvements in the NHS, finds a new poll by Ipos Mori commissioned by the NHS Confederation. More: Survey shows public support for NHS tax
read more© 1994 - 2026 B.M. Pharmaceuticals